1173 related articles for article (PubMed ID: 19623034)
1. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
2. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
Yemelyanova A; Vang R; Seidman JD; Gravitt PE; Ronnett BM
Am J Surg Pathol; 2009 Jun; 33(6):914-24. PubMed ID: 19295407
[TBL] [Abstract][Full Text] [Related]
3. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
[TBL] [Abstract][Full Text] [Related]
5. p16 expression in the female genital tract and its value in diagnosis.
O'Neill CJ; McCluggage WG
Adv Anat Pathol; 2006 Jan; 13(1):8-15. PubMed ID: 16462152
[TBL] [Abstract][Full Text] [Related]
6. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.
McCluggage WG; Connolly LE; McBride HA; Kalloger S; Gilks CB
Histopathology; 2012 Mar; 60(4):547-53. PubMed ID: 22250726
[TBL] [Abstract][Full Text] [Related]
7. IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas.
Zhang L; Liu Y; Hao S; Woda BA; Lu D
Am J Surg Pathol; 2011 Jun; 35(6):868-72. PubMed ID: 21566514
[TBL] [Abstract][Full Text] [Related]
8. P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin.
Saad RS; Mashhour M; Noftech-Mozes S; Ismiil N; Dubé V; Ghorab Z; Faragalla H; Khalifa MA
Int J Gynecol Pathol; 2012 Jan; 31(1):57-65. PubMed ID: 22123724
[TBL] [Abstract][Full Text] [Related]
9. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma.
McCluggage WG; Jenkins D
Int J Gynecol Pathol; 2003 Jul; 22(3):231-5. PubMed ID: 12819388
[TBL] [Abstract][Full Text] [Related]
10. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.
Schlosshauer PW; Ellenson LH; Soslow RA
Mod Pathol; 2002 Oct; 15(10):1032-7. PubMed ID: 12379748
[TBL] [Abstract][Full Text] [Related]
11. No metastatic cervical adenocarcinomas in a series of p16INK4a-positive mucinous or endometrioid advanced ovarian carcinomas: an analysis of the AGO Ovarian Cancer Study Group.
Wentzensen N; du Bois A; Kommoss S; Pfisterer J; von Knebel Doeberitz M; Schmidt D; Kommoss F
Int J Gynecol Pathol; 2008 Jan; 27(1):18-23. PubMed ID: 18156969
[TBL] [Abstract][Full Text] [Related]
12. p16, p14, p53, cyclin D1, and steroid hormone receptor expression and human papillomaviruses analysis in primary squamous cell carcinoma of the endometrium.
Horn LC; Richter CE; Einenkel J; Tannapfel A; Liebert UG; Leo C
Ann Diagn Pathol; 2006 Aug; 10(4):193-6. PubMed ID: 16844559
[TBL] [Abstract][Full Text] [Related]
13. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection.
Ansari-Lari MA; Staebler A; Zaino RJ; Shah KV; Ronnett BM
Am J Surg Pathol; 2004 Feb; 28(2):160-7. PubMed ID: 15043304
[TBL] [Abstract][Full Text] [Related]
14. Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas.
Siami K; McCluggage WG; Ordonez NG; Euscher ED; Malpica A; Sneige N; Silva EG; Deavers MT
Am J Surg Pathol; 2007 Nov; 31(11):1759-63. PubMed ID: 18059234
[TBL] [Abstract][Full Text] [Related]
15. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features.
Bartosch C; Manuel Lopes J; Oliva E
Adv Anat Pathol; 2011 Nov; 18(6):415-37. PubMed ID: 21993268
[TBL] [Abstract][Full Text] [Related]
16. Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma.
Sobel G; Németh J; Kiss A; Lotz G; Szabó I; Udvarhelyi N; Schaff Z; Páska C
Gynecol Oncol; 2006 Nov; 103(2):591-8. PubMed ID: 16797678
[TBL] [Abstract][Full Text] [Related]
17. Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium.
Onuma K; Dabbs DJ; Bhargava R
Int J Gynecol Pathol; 2008 Jul; 27(3):418-25. PubMed ID: 18580321
[TBL] [Abstract][Full Text] [Related]
18. Mammaglobin expression in gynecologic adenocarcinomas.
Hagemann IS; Pfeifer JD; Cao D
Hum Pathol; 2013 Apr; 44(4):628-35. PubMed ID: 23084633
[TBL] [Abstract][Full Text] [Related]
19. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
20. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
